Previous 10 | Next 10 |
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, will virtually participate in the 40 th Annual J.P. Morgan Healthcare Conference. Ying Huang, PhD, CEO and CFO of Legend Biotech, ...
Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today that Dr. Ying Huang, Legend Biotech’s Chief Executive Officer and Chief Financial Officer, has ...
Following a sharp decline on Wednesday amid concerns over an impending U.S. crackdown, Chinese biotech companies listed in the U.S. have rebounded sharply after the Department of Commerce published a list of sanctioned entities clarifying the earlier reports. Notable gainers include I-Mab (IM...
Shares of Legend Biotech (LEGN +4.6%) are up in afternoon trading despite initially falling in the premarket after pricing a $281.5M American Depository Shares offering. Shares were priced at $40 per ADS. Legend has foreign offices in China and Ireland. The company's lead candidate, cilta-cel...
Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it has priced an underwritten public of...
Legend Biotech (NASDAQ:LEGN) has priced its public offering of 7.5M American Depositary Shares (ADSs), each representing two ordinary shares, at $40.00 per ADS, for an anticipated net proceeds of ~$281.5M. Underwriters will have an option to purchase up to 1,125,000 additional ADSs. Net proce...
News that the Federal Reserve was primed to start fighting inflation sent U.S. stocks sharply higher on Wednesday. While monetary policy served as the main driver of trading, the session still featured a wide range of single-stock stories. Pfizer (NYSE:PFE) represented one of the standout per...
Shares of Legend Biotech (NASDAQ: LEGN) dropped 17.6% on Wednesday, falling more than $4 from the day before, though all the action came early. The stock, which closed at $48.54 on Tuesday, opened at $44 a share on Wednesday and fell to $39.37 early in the day before rebounding a bi...
Gainers: Biofrontera (NASDAQ:BFRI) +26%, Gemini Therapeutics (NASDAQ:GMTX) +19%, Vir Biotechnology (NASDAQ:VIR) +14%, Mesoblast (NASDAQ:MESO) +14%, Tandem Diabetes Care (NASDAQ:TNDM) +10% Losers: Atai Life Sciences (NASDAQ:ATAI) -24%, Alzamend...
Chinese biotech companies listed on U.S. financial markets are trading lower in the pre-market amid reports that the Biden administration is weighing tougher sanctions on China’s largest chipmaker, Semiconductor Manufacturing International Corp. (OTCQX:SMICY). A meeting scheduled for T...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...